ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 564

Levels of CXCL13 and sICAM1 Correlate with Disease Activity Score in Rheumatoid Arthritis (RA) Patients Treated with Tocilizumab (TCZ)

Katie Tuckwell1, Cem Gabay2, Thierry Sornasse1, Ruediger Laubender3, Jianmei Wang4 and Michael Townsend1, 1Genentech, Inc., South San Francisco, CA, 2University Hospitals of Geneva, Geneva, Switzerland, 3Roche Diagnostics, Penzberg, Germany, 4Roche Products Ltd., Welwyn Garden City, United Kingdom

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Biologics, biomarkers and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The biomarkers CXCL13 and sICAM1 have been associated with outcomes in patients with RA treated with TCZ. This study evaluated the association of CXCL13 and sICAM1 with disease activity and response to TCZ in early RA and DMARD-IR patients.

Methods: Patient subsets from the FUNCTION (early RA) and LITHE (DMARD-IR) clinical trials were selected based on baseline and Week 24 sample availability; serum CXCL13 and sICAM1 levels were measured. Correlations between CXCL13 and sICAM1 levels and DAS28-ESR at baseline, and between change in CXCL13 and sICAM1 levels and change in DAS28-ESR at Week 24, were determined. Changes in CXCL13 and sICAM1 levels from baseline to Week 24 were compared between treatment arms using Welch t test. The effect of treatment, baseline DAS28-ESR and baseline CXCL13 and sICAM1 levels on the likelihood of DAS28-ESR remission and ACR50 response at Week 24 was determined via logistic regression. DAS28-ESR remission and ACR50 rates were compared against CXCL13 and sICAM1 status (high vs low median values) within each trial arm using a Cochran-Mantel-Haenszel test.

Results: Overall, 458 of 872 patients from FUNCTION (TCZ + MTX, n = 160; TCZ monotherapy [TCZ-mono], n = 157; placebo [PBO] + MTX, n = 141) and 287 of 791 patients from LITHE (TCZ + MTX, n = 137; PBO + MTX, n = 150) were included. In these patient subsets, mean disease duration in FUNCTION was significantly shorter than in LITHE (0.45 vs 8.65 years). At baseline, correlation of serum CXCL13 levels with DAS28-ESR was moderate in the early RA population and weak in the DMARD-IR population (Table). Correlation between baseline serum sICAM1 levels and DAS28-ESR was low in both populations. Serum levels of CXCL13 decreased significantly at Week 24 in all treatment arms in both populations; sICAM1 levels decreased significantly at Week 24 in the TCZ-mono arm in patients with early RA and the TCZ + MTX arms in both populations but not in the PBO + MTX arms. Change in CXCL13 levels correlated moderately with change in DAS28-ESR at Week 24 in both populations (Table). Change in sICAM1 levels correlated moderately with change in DAS28-ESR at Week 24 in the DMARD-IR population but weakly in the early RA population. Although the treatment arm had a significant effect on the likelihood of DAS28-ESR remission and achievement of ACR50, the effect of baseline levels of CXCL13 and sICAM1 were not significant. DAS28-ESR remission and ACR50 response rates at Week 24 within each treatment arm of the early RA and DMARD-IR populations were not significantly different between patients with high vs low baseline CXCL13 and sICAM1 levels.

Conclusion: The association of baseline CXCL13 levels with RA disease activity was stronger in the early RA population than in the DMARD-IR population. Baseline levels of CXCL13 and sICAM1 did not predict response to TCZ at Week 24, suggesting that although these biomarkers are associated with disease activity, they do not predict response to TCZ in all RA populations.

 

Table. Correlation Between Serum CXCL13 and sICAM1 Levels and DAS28-ESR

 

Baseline

Week 24*

CXCL13

sICAM1

Δ CXCL13

Δ sICAM1

n

r

P value

n

r

P value

n

r

P value

n

r

P value

FUNCTION

(early RA)

458

0.36

< 0.0001

458

0.14

0.0029

458

0.33

< 0.0001

458

0.16

0.0005

LITHE

(DMARD-IR)

282

0.21

0.0003

282

0.17

0.0040

202

0.33

< 0.0001

202

0.26

0.0002

CXCL13, C-X-C motif chemokine ligand 13; DAS28-ESR, Disease Activity Score in 28 joints per erythrocyte sedimentation rate; DMARD-IR, inadequate response to disease-modifying antirheumatic drugs; RA, rheumatoid arthritis; sICAM1, soluble intercellular adhesion molecule 1.

* Correlation between change in CXCL13 and sICAM1 levels from baseline to Week 24 and change in DAS28-ESR from baseline to Week 24; all patients combined.

 


Disclosure: K. Tuckwell, Genentech, Inc., 3; C. Gabay, AB2 Bio, Pfizer and Roche, 2,AB2 Bio, AbbVie, Bristol Myers Squibb, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, UCB, 5, 8; T. Sornasse, Genentech, Inc., 3; R. Laubender, Roche Diagnostics, 3; J. Wang, Roche Products Ltd., 3; M. Townsend, Genentech, Inc., 3.

To cite this abstract in AMA style:

Tuckwell K, Gabay C, Sornasse T, Laubender R, Wang J, Townsend M. Levels of CXCL13 and sICAM1 Correlate with Disease Activity Score in Rheumatoid Arthritis (RA) Patients Treated with Tocilizumab (TCZ) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/levels-of-cxcl13-and-sicam1-correlate-with-disease-activity-score-in-rheumatoid-arthritis-ra-patients-treated-with-tocilizumab-tcz/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/levels-of-cxcl13-and-sicam1-correlate-with-disease-activity-score-in-rheumatoid-arthritis-ra-patients-treated-with-tocilizumab-tcz/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology